|
May 12, 2009
BioReliance
Corporation Announces the Establishment of a Liaison Office in India
Click here to
read the press release
January 6, 2009
BioReliance Corporation Announces Agreement with Barr Pharmaceuticals
to Supply Bulk Virus
for the Manufacture of Adenovirus Vaccine for the U.S. Department
of Defense.
Click here to read
the press release
November 20,
2008
BioReliance announced today the successful completion of
the first commercial application of its proprietary hybrid mycoplasma
(HyMy™) assay, combining the efficacy of the broth amplification
method of mycoplasma detection and the speed of qPCR detection to
cut the turnaround time by more than half on this vital, but lengthy
assay.
Click here to read the
press release
November 18,
2008
BioReliance Corporation announced today that it has concluded
an agreement with Provecs Medical GmbH, a company based in Hamburg,
Germany, for production of investigational quantities of Immunalon®,
a novel therapeutic agent based upon an adenovirus vector that stimulates
an immunological response against tumor cells.
Click here to read
the press release
November 13,
2008
BioReliance Corporation announced today that Dr. Sarah Sheridan,
a Scientific Director in BioReliance’s Glasgow, Scotland,
facility, will deliver a poster presentation regarding her work
in gene therapy biodistribution studies at the 16th Annual European
Society of Gene and Cell Therapy conference to be held from November
13-16, 2008 in Bruges, Belgium.
Click here to read the
press release
November 7, 2008
BioReliance announces the introduction of its new protein
array platform that offers greater sensitivity, reduced testing
time and reliable results. The platform, brand-named ReliArray™,
can simultaneously screen for four non-human pathogens in animal
serum.
Click here to read
the press release
October 14, 2008
BioReliance Corporation announced today that Andrew “Pat”
Paterson, Ph.D. has been named Senior Director/General Manager for
UK Operations. Dr. Paterson will report to Dr. James Kramer, Vice
President, Global Operations, Biologics of BioReliance.
Click here to read the
press release
September 10,
2008
BioReliance Corporation announces that its Rockville facilities
and staff have been significantly expanded to accommodate the growing
demand for its genetic toxicology (Gene Tox) testing services.
Click here to read the press release
August 26, 2008
BioReliance Corporation announced today that James J. Kramer,
Ph.D., has been appointed Vice President, Global Biologics Operations,
a newly created position.
Click here to read
the press release
August 5, 2008
BioReliance announces record adoption level of iNet™
electronic sample submission and tracking system.
Click
here to read the press release
June 3, 2008
BioReliance Corporation announced today that Tomoko Kotani
has been named Representative Director, BioReliance KK, the company’s
new commercial office in Tokyo. Ms. Kotani will be responsible for
commercial operations in Japan.
Click
here to read the press release
May 7, 2008
BioReliance Corporation announced today that Donna Klein
has been named Vice President, Human Resources, responsible for
the human resource functions for all the company’s locations
including the United States, United Kingdom and Asia.
Click here to read the press release
April 22, 2008
BioReliance Corporation announced today that John L. Kolman,
PhD, has been named Senior Director, Research and Development.
Click here to
read the press release
April 10, 2008
BioReliance Corporation announces that registration is now
open for its 2008 Technical Seminar, “Current Concepts in
Biologics Safety Testing.” The one-day seminar will be offered
in
Copenhagen, Denmark, on May 28.
Click here to read
the press release
April 8, 2008
BioReliance Corporation announced today Darryl L. Goss has
been appointed Vice President, Toxicology/Laboratory Animal Diagnostic
Services (LADS), a new executive position created to lead this newly
formed Business Unit.
Click here to read the
press release
March 25, 2008
BioReliance Corporation has established a commercial office
in Tokyo, expanding its operations to significantly address the
growth opportunities in the Asia Pacific markets.
Click here
for more details in English.
Click here for more details
in Japanese.
February 28,
2008
BioReliance Offers 2008 Training Program: Guidelines for
Successful Biologics Safety Testing
The seminar will be offered in two locations: La Jolla, CA on April
3rd, and in Rockville, MD on May 8th. There is no fee for attendance,
and complimentary breakfast and lunch will be served. Topics will
include: Biologics Testing, Clearance Services and Cleaning Strategies;
Regulatory Trends and Validation Requirements; and Selecting a Contract
Testing Organization.
Click
here to read the press release.
February 28,
2008
BioReliance to Host 22nd Annual Genetic and Molecular Toxicology
Workshop
The workshop is scheduled for April 17-18, 2008, at the Gaithersburg
Marriott Hotel, Gaithersburg, MD. Topics include: regulatory aspects
of genetic toxicology; genetic toxicology test batteries, the theoretical
basis for each test system; protocol design, assay limitations,
dealing with positive results; interpretation of data; case studies;
and, the use of predictive screening assays. A tour of the genetic
toxicology laboratory is included.
Click here
to read the press release.
January 8, 2008
James Kramer joins Bioreliance
James J. Kramer, Ph.D, joins BioReliance as Vice President of Operations,
U.S. Biologics. In his new position, Dr. Kramer is the US Biologic
Services Value Stream leader for the company and has direct ownership
for Program Management, Quality, GMP-Cell Banking, Clearance Services,
Molecular Biology, Cell Biology Microbiology, Virology, In-Vivo
Studies, Support Services and Facilities.
Click here to read the press release.
October 29, 2007
BioReliance Appoints Executive Chairman to be Interim CEO
and Announces Recent Senior Executive Additions
BioReliance Corporation has appointed its Executive Chairman, Charles
C. Harwood, Jr., to the additional post of Interim CEO, following
the announced resignation of Tim Derrington from the CEO position.
In addition, BioReliance announced that three senior executives
have joined the company since June: David E. Onions, Ph.D., as Chief
Scientific Officer, David S. Walker as Chief Financial Officer,
and Darryl L. Goss as Vice President of Global Process Excellence.
Click here to read
the press release.
October 10th,
2007
BioReliance Launches Next-Generation Genotoxicity Screening
Service
BioReliance has contracted with Gentronix to offer their GreenScreen
HC in vitro assay as a major part of BioReliance's portfolio
of genotoxicity screening services. GreenScreen HC, in conjunction
with Ames II assays, allows pharmaceutical companies to test for
genotoxic potential earlier in the preclinical development process,
using only a few milligrams of test compound as opposed to the gram
quantities required by current ICH regulatory tests.
Click here to read the
press release.
September 18th,
2007
BioReliance Corporation Launches iNet™ for Online
Results Tracking of Biological Safety Tests BioReliance is pleased
to announce the release of iNet, a proprietary information technology
system for submitting and tracking test article details via a controlled
and secure Internet access from any location worldwide. Now you
can view the status of current and past studies, keep informed of
when testing will be completed, download reports, and allow your
colleagues to view the status of your tests. Click here to read
the press release.
Click here to read the press
release.
April 30, 2007
David Onions, Ph. D., appointed Chief Scientific Officer
of BioReliance Corporation
Click
here to go to the article (PDF
version)
April 12, 2007
Avista Capital Partners acquires BioReliance Corporation
for approximately $210 million
Click
here to go to the article (PDF
version)
February 13, 2007
Avista Capital Partners announces intent to acquire BioReliance
Corporation from Invitrogen Corporation
Click
here to go to the article (PDF
version)
| 
